Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China
Article in Emerging Microbes & Infections (March 2024)
The most recent citing publications are shown below. View all 35 publications that cite this research output on Dimensions.
DeepSP: Deep Learning-Based Spatial Properties to Predict Monoclonal Antibody Stability
Preprint in bioRxiv (March 2024)
Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume
Article in mAbs (November 2023)